767 related articles for article (PubMed ID: 16337092)
61. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.
Ferrari CC; Pott Godoy MC; Tarelli R; Chertoff M; Depino AM; Pitossi FJ
Neurobiol Dis; 2006 Oct; 24(1):183-93. PubMed ID: 16901708
[TBL] [Abstract][Full Text] [Related]
62. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
Dluzen DE; McDermott JL
J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
[TBL] [Abstract][Full Text] [Related]
63. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Jakowec MW; Petzinger GM
Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
[TBL] [Abstract][Full Text] [Related]
64. Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice.
L'episcopo F; Tirolo C; Testa N; Caniglia S; Morale MC; Impagnatiello F; Marchetti B
Rejuvenation Res; 2011 Aug; 14(4):411-24. PubMed ID: 21793734
[TBL] [Abstract][Full Text] [Related]
65. Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Zhang J; Yang B; Sun H; Zhou Y; Liu M; Ding J; Fang F; Fan Y; Hu G
Neurosci Lett; 2016 Feb; 614():7-15. PubMed ID: 26748031
[TBL] [Abstract][Full Text] [Related]
66. Neuroinflammatory processes in Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
[TBL] [Abstract][Full Text] [Related]
67. Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Barnum CJ; Tansey MG
Prog Brain Res; 2010; 184():113-32. PubMed ID: 20887872
[TBL] [Abstract][Full Text] [Related]
68. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
Yantiri F; Andersen JK
IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588
[TBL] [Abstract][Full Text] [Related]
69. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.
Fahrig T; Gerlach I; Horváth E
Mol Pharmacol; 2005 May; 67(5):1544-55. PubMed ID: 15716464
[TBL] [Abstract][Full Text] [Related]
70. [Experimental models of Parkinson's disease].
Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
[TBL] [Abstract][Full Text] [Related]
71. Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Mitra S; Ghosh N; Sinha P; Chakrabarti N; Bhattacharyya A
Neurosci Lett; 2016 Mar; 616():86-92. PubMed ID: 26827723
[TBL] [Abstract][Full Text] [Related]
72. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.
Gao HM; Jiang J; Wilson B; Zhang W; Hong JS; Liu B
J Neurochem; 2002 Jun; 81(6):1285-97. PubMed ID: 12068076
[TBL] [Abstract][Full Text] [Related]
73. Microglia Polarization, Gene-Environment Interactions and Wnt/β-Catenin Signaling: Emerging Roles of Glia-Neuron and Glia-Stem/Neuroprogenitor Crosstalk for Dopaminergic Neurorestoration in Aged Parkinsonian Brain.
L'Episcopo F; Tirolo C; Serapide MF; Caniglia S; Testa N; Leggio L; Vivarelli S; Iraci N; Pluchino S; Marchetti B
Front Aging Neurosci; 2018; 10():12. PubMed ID: 29483868
[TBL] [Abstract][Full Text] [Related]
74. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models.
Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS
Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193
[TBL] [Abstract][Full Text] [Related]
75. Apoptosis and Parkinson's disease.
Lev N; Melamed E; Offen D
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):245-50. PubMed ID: 12657363
[TBL] [Abstract][Full Text] [Related]
76. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
Gillies GE; Murray HE; Dexter D; McArthur S
Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
[TBL] [Abstract][Full Text] [Related]
77. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
Teismann P; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
[TBL] [Abstract][Full Text] [Related]
78. Parkinson's disease: contemporary state and perspectives.
Mokrý J
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1994; 37(1):5-12. PubMed ID: 7761792
[TBL] [Abstract][Full Text] [Related]
79. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
Collins LM; Toulouse A; Connor TJ; Nolan YM
Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
[TBL] [Abstract][Full Text] [Related]
80. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Bourque M; Dluzen DE; Di Paolo T
Front Neuroendocrinol; 2012 Apr; 33(2):169-78. PubMed ID: 22387674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
